Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention

被引：79
作者：
Garcia-Vidal, C. [1 ,2 ]
Rodriguez-Fernandez, S. [2 ]
Teijon, S. [2 ]
Esteve, M. [3 ]
Rodriguez-Carballeira, M. [2 ]
Lacasa, J. M. [2 ]
Salvador, G. [4 ]
Garau, J. [2 ]
机构：
[1] Hosp Univ Bellvitge, Infect Dis Serv, Barcelona 08907, Spain
[2] Univ Barcelona, Hosp Mutua Terrassa, Serv Internal Med, Barcelona, Spain
[3] Univ Barcelona, Hosp Mutua Terrassa, Serv Gastroenterol, Barcelona, Spain
[4] Univ Barcelona, Hosp Mutua Terrassa, Serv Rheumatol, Barcelona, Spain
来源：
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 2009年 / 28卷 / 04期
关键词：
TUBERCULIN SKIN-TEST; NECROSIS-FACTOR ANTAGONISTS; FACTOR-ALPHA ANTAGONISTS; GAMMA RELEASE ASSAYS; RHEUMATOID-ARTHRITIS; LATENT TUBERCULOSIS; HEPATITIS-B; THERAPY; METHOTREXATE; REACTIVATION;
D O I：
10.1007/s10096-008-0628-x
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
We sought to determine factors associated with opportunistic infections (OI) in infliximab-treated patients. A retrospective study cohort (1999-2004) was examined. Nine OI were diagnosed in 94 infliximab-treated patients: tuberculosis (four), visceral leishmaniasis (one), pyogenic muscular abscess (one Salmonella spp. and one Streptococcus pneumoniae), and two viral infections (hepatitis B virus [HBV] and zoster ophthalmicus). The risk for OI was significantly higher in the first year of treatment (odds ratio [OR] 8; 95% confidence interval [CI] 2-50). Previous treatment with more than two immunosuppressive drugs was the only factor related to OI (OR 8.686; 95% CI 1.889-39.943). We identified the subset of patients treated with infliximab who had a higher risk for OI. The screening of latent infections is key to diminishing the incidence of these infections.
引用
收藏
页码：331 / 337
页数：7
相关论文
共 50 条
  • [21] Infections during extracorporeal membrane oxygenation: epidemiology, risk factors, pathogenesis and prevention
    Biffi, Stefano
    Di Bella, Stefano
    Scaravilli, Vittorio
    Peri, Anna Maria
    Grasselli, Giacomo
    Alagna, Laura
    Pesenti, Antonio
    Gori, Andrea
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 (01) : 9 - 16
  • [22] Opportunistic Infections, Mortality Risk, and Prevention Strategies in Patients With Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome
    Czech, Mary
    Cuellar-Rodriguez, Jennifer
    Patel, Bhavisha A.
    Groarke, Emma M.
    Cowen, Edward W.
    Turturice, Benjamin
    Beck, David B.
    Wilson, Lorena
    Goodspeed, Wendy
    Darden, Ivana
    Young, Neal S.
    Hickstein, Dennis
    Ombrello, Amanda
    Hoffman, Patrycjia
    Arikan, Evsen Apaydin
    Sinaii, Ninet
    Hathaway, Londa
    Castelo-Soccio, Leslie
    Fike, Alice
    Kastner, Daniel B.
    Grayson, Peter C.
    Ferrada, Marcela A.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (07):
  • [23] Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections
    Schneeweiss, S.
    Korzenik, J.
    Solomon, D. H.
    Canning, C.
    Lee, J.
    Bressler, B.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (03) : 253 - 264
  • [24] Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data
    Teresa A. Simon
    Lixian Dong
    Kevin L. Winthrop
    [J]. Arthritis Research & Therapy, 23
  • [25] Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data
    Simon, Teresa A.
    Dong, Lixian
    Winthrop, Kevin L.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [26] Risk factors for infection in haematology patients treated with rituximab
    Kanbayashi, Yuko
    Nomura, Kenichi
    Fujimoto, Yoshiko
    Yamashita, Mihoko
    Ohshiro, Muneo
    Okamoto, Kousuke
    Matsumoto, Yosuke
    Horiike, Shigeo
    Takagi, Tatsuya
    Ishida, Yoji
    Taniwaki, Masafumi
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 82 (01) : 26 - 30
  • [27] Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab
    Heusele, Marion
    Clerson, Pierre
    Guery, Benoit
    Lambert, Marc
    Launay, David
    Lefevre, Guillaume
    Morell-Dubois, Sandrine
    Maillard, Helene
    Le Gouellec, Noemie
    Hatron, Pierre-Yves
    Hachulla, Eric
    [J]. CLINICAL RHEUMATOLOGY, 2014, 33 (06) : 799 - 805
  • [28] Incidence of opportunistic infections in patients with rheumatoid arthritis treated with different molecular-targeted drugs: A population-based retrospective cohort study
    Takabayashi, Katsuhiko
    Ando, Fumihiko
    Ikeda, Kei
    Nakajima, Hiroshi
    Hanaoka, Hideki
    Suzuki, Takahiro
    [J]. MODERN RHEUMATOLOGY, 2023, 33 (06) : 1078 - 1086
  • [29] Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa
    Fenner, Lukas
    Reid, Stewart E.
    Fox, Matthew P.
    Garone, Daniela
    Wellington, Maureen
    Prozesky, Hans
    Zwahlen, Marcel
    Schomaker, Michael
    Wandeler, Gilles
    Kancheya, Nzali
    Boulle, Andrew
    Wood, Robin
    Henostroza, German
    Egger, Matthias
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2013, 18 (02) : 194 - 198
  • [30] Screening of adult dental patients visiting Khyber College of Dentistry, Peshawar for HBV and HCV infections and identifying the associated risk factors
    Haider, Jamila
    Lufullah, Ghosia
    Nazli, Rubina
    Akhtar, Tasleem
    Shah, Asma
    [J]. PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2017, 33 (03) : 615 - 620
12345